CJC-1295 + Ipamorelin (Blend)
/ Two-component vendor blend — CJC-1295 (with or without DAC; vendors vary) plus ipamorelin (selective GHS-R1a hexapeptide)ALIAS · CJC-1295/Ipamorelin · Mod-GRF + Ipamorelin · IPA/CJC blend · Classic GH stack
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 for the combination. Each component independently has the evidence reviewed under its own peptide page. The blend has no published combination pharmacology trial. The most-discussed peptide stack on research-vendor and bodybuilding forums.
The pharmacological rationale is convergent stimulation of pituitary GH release through two receptor pathways — CJC-1295 via the GHRH receptor and ipamorelin via the ghrelin (GHS-R1a) receptor. In animal pharmacology, GHRH agonist plus GHS-R1a agonist produces synergistic GH peaks compared with either alone; the principle is established class biology, but no published human trial of this specific combination exists.
None for the combination. Component evidence: CJC-1295 with DAC has a single 2006 Phase 1 study (tier 4); CJC-1295 without DAC has no published clinical data; ipamorelin reached Phase 2 in postoperative ileus and orthopedic recovery without clear efficacy translation.
No combined safety database. Each component carries minimal individual human safety data (CJC-1295 with DAC has Phase 1 only; ipamorelin Phase 2 short-term only). Predicting combined effects from components is inference, not data.
Regulatory status
- FDA status:
- Not FDA-approved
Vendor presentations of CJC-1295/Ipamorelin as an established 'protocol' are not supported by clinical-trial evidence at the dose ratios or schedules typically marketed. The pharmacological rationale is sound; the human safety and efficacy database is essentially empty.